Fox Business - The Power to Prosper
Search Site

Eli Lilly

Lilly CEO sees margins hitting pre-patent cliff levels by ‘19

Eli Lilly CEO John Lechleiter discusses 2Q earnings and the impact of recent patent expirations.

Read More

  1. Biotechs with big goals, but no office space or full-time employees?

    Alkeus Pharmaceuticals CEO Leonide Saad on the company’s research.

  2. The next golden age of M&A

    Citigroup Institutional Clients Group vice Chairman Leon Kalvaria gives his outlook for the M&A market.

  3. Zimmer to Buy Biomet In $13.35B Deal

    Medical device maker Zimmer Holdings Inc said it would buy orthopedic products company Biomet Inc in a deal valued at about $13.35 billion to broaden its portfolio o...

  4. Lilly Sales Below Views, Trims Profit Forecast

    U.S. drugmaker Eli Lilly and Co reported lower-than-expected quarterly revenue on Thursday, hurt by disappointing sales of its cancer and diabetes drugs.Lilly said i...

  5. Pharma Deal Frenzy: A Bid to Boost Profits

    High-priced pharmacy deals are all the rage this year as big drug companies stung by patent expirations attempt to offset losses and reduce risk and costs by joining...

  6. Amgen Slumps After 1Q Earnings Miss

    Amgen (NASDAQ:AMGN) said Tuesday its first-quarter profit dropped 25% amid lower-than-expected sales for the biopharmaceutical firm.The company reported net income o...

  7. Novartis focusing on three giant areas

    Novartis CEO Joe Jimenez on his company’s corporate transformation and focus on pharmaceuticals, eyecare and generics.

  8. U.S. futures look for direction

    FBN’s Maria Bartiromo on U.S. futures and the $25 billion in Novartis deals.

  9. Novartis Announces Multi-Billion-Dollar Revamp

    Novartis (NYSE:NVS) is revamping its portfolio with a flurry of deals worth about $25 billion, as the Swiss pharmaceutical giant plans to swap assets with GlaxoSmith...

  10. M&A Buzz Boosts Markets

    FOX Business: Capitalism Lives HereA jolt of deal-making in the biotechnology sector, combined with generally upbeat earnings news, sent Wall Street climbing higher....

  11. Stock Futures Steady Amid Raft of Health M&A

    FOX Business: Capitalism Lives HereU.S. stock-index futures were little changed on Tuesday as traders eyed a slew of merger activity in the pharmaceutical sector. To...

  12. Wall Street Ticks Up as Traders Parse News Deluge

    FOX Business: Capitalism Lives HereU.S. stocks inched higher on Tuesday as traders reviewed a flood of corporate earnings and deal news.Today's MarketsAs of 9:32 a.m...

  1. Eli Lilly 2Q earnings beat expectations

    Earnings HQ: FBN’s Ashley Webster breaks down Eli Lilly ’s second-quarter earnings report.

  2. Spending on pets surges

    Aratana Therapeutics CEO Steven St. Peter on what’s driving growth in the animal-health business.

  3. Eli Lilly CEO on cancer: We’re in store for further advances

    Eli Lilly CEO John Lechleiter on where we are in the fight for cancer.

  4. Eli Lilly CEO talks pipeline growth

    Eli Lilly CEO John Lechleiter gives his outlook for growth and new products.

  5. Eli Lilly CEO talks M&A

    Eli Lilly CEO John Lechleiter argues the company doesn’t need to make bid deals to grow.

  6. How to bring cash back to America

    Schulte, Roth & Zabel managing partner Paul Roth weighs in on the U.S. corporate tax rate.

  7. The health-care stocks to boost your portfolio

    Rehmann Financial Principal Joe Heider on the health-care stocks to watch.

‹ Prev12345Next ›
Freebase CC-BY
Source: Eli Lilly on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL